沙利度胺联合VAD方案治疗多发性骨髓瘤疗效分析  

Analysis of Curative Effect of Thalidomide and VAD Plan in Treatment of Multiple Myeloma

作　　者：胡娜[1] HU Na(Department of Hematology,Shuyang People's Hospital,Shuyang,Jiangsu Province,223600 China)

机构地区：[1]沭阳县人民医院血液科,江苏沭阳223600

出　　处：《中外医疗》2017年第34期116-118,共3页China & Foreign Medical Treatment

摘　　要：目的观察对多发性骨髓瘤患者采取沙利度胺的方案进行治疗后的效果。方法方便选取2012年6月—2017年6月该院多发性骨髓瘤患者60例将其依据动态随机化原则分2组,30例为一组。一组给予VAD(长春地辛+表阿霉素+地塞米松)联合沙利度胺为主治疗(对照组),另一组应用CTD(环磷酰胺+地塞米松+沙利度胺)(观察组),对比2组M蛋白数据、骨髓细胞数据、β2-MG数据、血红蛋白数据,以及发生的不良反应状况。结果观察组多发性骨髓瘤患者在治疗后,M蛋白平均(22.15±8.05)×10-2,骨髓细胞平均(11.62±5.06)×10-2,β2-MG平均(2.45±0.71)mg/L,血红蛋白平均(120.62±15.48)g/L,不良反应总数据为33.33%,各指标得到良好改善,和对照组相比,4项客观指标的差有统计学意义(P<0.05),但不良反应情况对比差异无统计学意义(P>0.05)。结论在使用VAD的基础上,针对多发性骨髓瘤患者再联合实施沙利度胺的方案治疗,其效果更为理想。Objective To observe the effect of thalidomide and VAD plan in treatment of multiple myeloma.Methods 60 cases of patients with multiple myeloma in our hospital from June 2012 to June 2017 were convenient selected and randomly divided into two groups with 30 cases in each,he control group were treated with VAD(vindesine,pharmorubicin,dexamethasone)combined with thalidomide,while the observation group were treated with CTD(cyclophosphamide,dexamethasone and thalidomide),and the M protein data,bone cell data,β2-MG data,hemoglobin data and adverse reactions were compared between the two groups.Results After treatment,the average levels of M protein data,bone cell data,β2-MG data,hemoglobin data and total data of adverse reactions were respectively(22.15±8.05)×10-2,(11.62±5.06)×10-2,(2.45±0.71)mg/L,(120.62±15.48)g/L,33.33%,and various indexes were improved and differences between groups were obvious(P<0.05),but the difference in the adverse reaction between the two groups was not big(P>0.05).Conclusion The effect of thalidomide on the basis of the VAD in treatment of patients with multiple myeloma is ideal.

关 键 词：VAD CTD 沙利度胺 多发性骨髓瘤 

分 类 号：R733.3[医药卫生—肿瘤]